HealthEquity price target raised to $80 from $62 at Jefferies 08:21 HQY Jefferies analyst Glen… Alright this is the 2nd upgrade in so many weeks. I am very familiar with this company.> HQY ADDED TO WATCH LIST******
Van gave me this idea a ways back-Italian outfit.- It crashed with all the sports gaming stks. Elys Game Technology sees FY21 revenue up 22%, consensus $47.46M 08:07 ELYS Elys Game Technology reported that management expects revenues to increase by approximately 22% to approximately $45.5M for the fiscal year ended December 31, 2021, subject to final audit verification, compared to approximately $37.3M for the fiscal year ended December 31, 2020. The company said, "Additionally, we expect web-based gross gaming revenue to increase by approximately 74% to approximately $54.9 million for the fiscal year ended December 31, 2021, subject to final audit verification, compared to approximately $31.6 million for the fiscal year ended December 31, 2020. Our recent entry into the US B2B market has had a very positive effect on our service related business, although still relatively small, our revenues in this segment have grown to approximately $1 million for the fiscal year ended December 31, 2021, an improvement of approximately 627%, subject to final audit verification." Michele Ciavarella, executive chairman of Elys, commented, "We are very pleased with the growth of our European operations demonstrating the value of early investments we made to develop our Newgioco brand in the Italian market and the streamlining of operations under the Multigioco subsidiary thereby eliminating the duplication of license management. Multigioco benefited from the completion of our Ulisse operations which were organized in the EU while operating in Italy. As reported in mid-2021, the Company phased out the Ulisse operations due to the impact of COVID restrictions on their land-based distribution resulting in a non-cash impairment of $4.8 million. We expect to win further B2C margin improvement by streamlining Multigioco operations as we grow our omni-channel distribution strategy and establish plans to roll-out the land-based channel of our powerful Elys Gameboard technology on a B2B basis in Europe."
https://elitetrader.com/et/threads/gba-presents-the-bare-essentials.365622/page-68#post-5568792 https://elitetrader.com/et/threads/gba-presents-the-bare-essentials.365622/page-68#post-5568790
ASO has so been dissed here at this point we are moving on-- I have done a rare pre market trade. ASO SOLD @ 36.80+0.27(+0.74%) Why? Because Van has jinxed it I can tell he knows something that's why he highlighted ASO. I like to get $10 a share but we wil take what we can get.--- Pre-M Cleveland-Cliffs price target raised to $46 from $37 at B. Riley 07:52 CLF XPO Logistics price target raised to $105 from $95 at Raymond James 07:28 XPO Uranium Royalty expands physical uranium holdings 07:22 UROY <<<< BIOTECH UPDATE >>>> I have absolutely no proof of concept here but I have a feeling Biotech is about to raise from the dead.///// WATCH->Cara Therapeutics announces data from sub-study of KARE Phase 2 trial 07:22 CARA Cara Therapeutics announced data from a sub-study of the KARE Phase 2 clinical trial demonstrated Oral KORSUVA improved itch and inflammatory biomarkers in atopic dermatitis, AD, patients with moderate-to-severe pruritus. The biomarker data were presented during the Late-Breaking Research: Clinical Trials session at the 2022 American Academy of Dermatology, AAD, Annual Meeting. The sub-study, which included 40 patients from the KARE trial, characterized the effect of Oral KORSUVA on pruritus- and AD-related gene expression using baseline and week 12 skin biopsies. Data pooled from all Oral KORSUVA treatment groups indicated treatment with Oral KORSUVA altered expression of multiple individual pruritus- and AD-related genes. Gene set variation analysis confirmed downregulation of pruritus-related genes and the Th2 pathway following 12 weeks of treatment with Oral KORSUVA, but not placebo. WATCH-> Oncorus initiated with a Buy at H.C. Wainwright 06:07 ONCR H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Oncorus with a Buy rating and $7 price target. Oncorus is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies with enhanced systemic activity in cancerous tissue while sparing healthy tissue, Ramakanth tells investors in a research note. With two unique platforms, a "de-risked" clinical program, and cash position of $124M, Oncorus is undervalued and provides for an attractive entry point for long-term investors, says the analyst. WATCH-> Citi opens '90-day positive Catalyst Watch' on Aldeyra into dry eye data 06:23 ALDX IRA alert*American Express price target raised to $223 from $218 at Morgan Stanley 07:10 AXP Morgan Stanley Pure Storage price target raised to $43 from $36 at KeyBanc 06:33 PSTG KeyBanc analyst Thomas… Imagine owning Pure Storage through a Bear market and being UP so Much! What a rare find. Amazon's delivery drones have crashed at least 8 times, Insider reports 06:28 AMZN Documents show Amazon's prototype delivery drones have crashed at least eight times in the last year, Business Insider's Katherine Long reports. Confirmation of the crashes comes as Amazon looks to secure new registration that would allow it to test drones closer to population centers and with fewer restrictions, the report says.
Van your lazy way of searching is revealing a lot. I asked you a question which like so many you did not answer--- My HF buddies are getting into Mexico debt and looking at oil rich SA bonds and companies... I simple said hey we need some exposure and asked you for help. I put out these relatively unknown Brazilian plays as ideas to consider- So you A) Don't reply B) Don't care Whatever-- But then you want to knock me for asking a question... We kind of need Brazil or Mexico exposure/ Country Fund? I doubt there could be one trading at a discount to NAV which is the way I used to buy these Closed End Country Funds...... Van : Brazil banks Next up are the three Brazilian banks: Banco Santander (NYSE:BSBR) +11.6%, Banco Bradesco (NYSE:BBD) +11% and Itau Unibanco +9.5%.
Stoney... No one knows what are ideas, watch list, none of the above... how many times in the last three threads have I used the word "definiteness"? If you have a solid pick, state it. Whether you buy it or not. Say "this is a buy right here". That's all we're asking. You can't put out dozens of stocks per week, and then crow when one of them goes up. I mean you can, but it doesn't mean anything without definitive entry calls. Period.
March 8th or so CARA had a vol stk and moved out from $10.60 area> Cara Therapeutics, Inc. (CARA) NasdaqGM - 12.34+0.02(+0.16%) At close: March 25 04:00PM EDT 12.50+0.16(+1.30%) Pre-Market:07:00AM EDT
Van you don't seem to be able to keep up. Everyone else is not having a problem. I just showed you how your blind searching backfires on you every time and so it has again. At this point I'll just stop asking you for advice because you hold it against me-- I'll find my own Brazil plays.
No insights on ASO btw. As I said before, I think the whole sector is cheap. That's why I said to close RH. Multiple contraction as compared to its peers, albeit upper end type stuff. It could easily take a 15% hit and still have a high PE compared to some of the others.